Research Analysts Offer Predictions for BioXcel Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:BTAI)

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for BioXcel Therapeutics in a report issued on Monday, April 15th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.51) for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.61) EPS.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.22. BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. The firm had revenue of $0.38 million during the quarter, compared to the consensus estimate of $1.17 million.

Several other research firms also recently commented on BTAI. UBS Group reiterated a “neutral” rating and issued a $4.00 price objective (down from $9.00) on shares of BioXcel Therapeutics in a report on Wednesday, February 21st. Canaccord Genuity Group reduced their price objective on BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, March 14th. Finally, Bank of America reduced their price objective on BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, March 13th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $16.86.

BioXcel Therapeutics Stock Performance

NASDAQ BTAI opened at $2.59 on Wednesday. BioXcel Therapeutics has a one year low of $1.91 and a one year high of $29.56. The stock has a 50-day moving average of $2.91 and a 200 day moving average of $3.18. The company has a market capitalization of $79.20 million, a price-to-earnings ratio of -0.42 and a beta of 0.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp lifted its position in shares of BioXcel Therapeutics by 17.7% during the 2nd quarter. State Street Corp now owns 2,072,199 shares of the company’s stock valued at $13,801,000 after buying an additional 311,516 shares in the last quarter. BlackRock Inc. raised its stake in BioXcel Therapeutics by 2.8% during the 3rd quarter. BlackRock Inc. now owns 1,463,372 shares of the company’s stock valued at $17,297,000 after purchasing an additional 40,025 shares during the period. Wellington Management Group LLP bought a new stake in BioXcel Therapeutics during the 1st quarter valued at approximately $24,904,000. Vanguard Group Inc. raised its stake in BioXcel Therapeutics by 8.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,220,530 shares of the company’s stock valued at $3,088,000 after purchasing an additional 91,808 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in BioXcel Therapeutics by 91.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 668,370 shares of the company’s stock valued at $1,691,000 after purchasing an additional 318,910 shares during the period. 30.68% of the stock is owned by hedge funds and other institutional investors.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.